Active Specific Immunotherapy in the Management of Adenocarcinoma of the Pancreas

Active specific immunotherapy for pancreatic adenocarcinoma and subsequent immunohistochemical analysis of tumour tissue have not been previously reported. To date, the therapy of pancreatic adenocarcinoma has been largely unsuccessful. A patient treated with a therapeutic ‘cancer vaccine’ and the immunological impact on the primary tumour of this potential new therapy are described. To the authors’ knowledge, this is both the first patient to be treated with active specific immunotherapy for pancreatic adenocarcinoma and the first to be studied immunologically by flow cytometry and immunohistochemistry with an apparent positive clinical impact